What is Braftovi used to treat?

Braftovi is used to treat patients with unresectable or metastatic melanoma (skin cancer that has spread) with a BRAF V600E or V600K gene mutation, as detected by an FDA-approved test.

Braftovi (encorafenib) from Array BioPharma, along with Mektovi (binimetinib), is part of an oral BRAF/MEK inhibitor combination therapy. Both Braftovi and Mektovi are kinase inhibitors.

Roughly 50% of patients diagnosed with metastatic melanoma test positive for the BRAF mutation, and it is the most common genetic mutation in metastatic melanoma.

Braftovi is not indicated for the treatment of patients with wild-type BRAF melanoma.